Arcturus Therapeutics Ltd. (ARCT) Stock Discussions on Social Media

I am in here

Raymond James analyst Steven Seedhouse stated in a note to the firm's clients that the efficacy for ARCT-021 with a single dose could be as low as 62%. That's a disappointing level compared to Pfizer's efficacy of 95% and Moderna's 94%.

Merck gave up on their Covid vaccine. Isn’t that good news for arct?

Moderna plans to begin their annual booster study for July 2021. So, one year after getting dose 2, Moderna is at least planning for the possibility that protection will wane. Tal Zaks sees the possibility that Covid will be an annual vaccine, much like the flu.

The team opened the press release extolling the virtues of the ARCT vaccine: Low single dose and lyophilized product. We have heard those before. Moving on to Phase II - OK, sounds like it’s progressing well. Then came the macaque test results (Slide 4) - still sounding good. Almost everything after that was about defending the idea that T cell response is more important than neutralizing antibodies. Slides: https://ir.arcturusrx.com/static-files/7f1f7674-71b0-4276-8b88-339c3e51b671Press conference: http://public.viavid.com/index.php?id=142847The team wanted everybody to know that cellular immunity (T cells, CD4+ & CD8+ responses, Slides 12 to 14) was more important than the humoral immunity (Binding antibodies, neutralizing antibodies, Slides 10 to 11). What did not help was that good preclinical data for the titer counts did not translate to the Phase I/II results. The hardest to swallow was Slide 11 because the neutralizing antibodies were not showing up. That is why the floor opened below the stock price today. Everybody was focused on the neutralizing antibody counts because Pfizer & Moderna had good neutralizing antibody counts and they had impressive efficacy charts (slide 18) to show. Today’s press release was a clear disappointment for those looking at neutralizing antibody counts. Having scored very well in eliminating fatalities in hACE2 transgenic mice and macaque models, the team realized something was wrong with just looking at neutralizing antibody counts. Some things did not add up; convalescent COVID-19 serum figures for recovered patients had a wide distribution (Slide 11) but all remained protected from re-infection, breakthrough infection in mice when CD8+ T cells were removed vs no issues when B cells (humoral immunity) were removed (Slide 21), patients with antibody disorders were able to mount a good resistance against the COVID-19 virus with T-cell responses (Slide 22), proven T-cell role in MMR infections (Slide 23), the case of high dengue viral load even with high antibody count which came down only after CD8+ T-cells showed up (Slide 24).The anecdotal examples seemed to tell a story that cellular immunity is the way to go and the team was keen to prove the case in Phase III trials. By not going direct to Phase II/III trials, the team might have averted a situation of getting caught at the wrong end of trial framework changes - wise move! Better to have a checkpoint at end of Phase II than to have “completed” Phase II/III only to find out that the rules have changed. ARCT-021 could be the vaccine to prove that cellular immunity (without humoral immunity) continues to show high efficacy in preventing COVID-19 disease. High-risk moment when we make it to the efficacy chart.The Phase I/II cellular immunity responses support the case for ARCT-021 as a single dose at 7.5 mcg. The 5 mcg / 7.5 mcg prime-boost cohorts are insurance and data points to prove that prime-boost only offer marginal benefit over a single dose at 7.5 mcg.Links to info that support the cellular immunity argument:Discussion on how ongoing vaccine efforts are focused on neutralizing antibodies. There will be a need for new approaches (other than looking at neutralizing antibodies) if problems emerge in the vaccinated population with breakthrough infections, waning antibody levels after vaccination and/or emergence of new viral strains. https://immunology.sciencemag.org/content/5/53/eabe8063Long-lasting cellular immunity of SARS patients after recovery and T-cells that offer robust cross-reactivity to the N protein of SARS-CoV-2. https://www.nature.com/articles/s41586-020-2550-z“Strong evidence that T cell immunity to SARS-CoV-2 may last longer than antibody immunity.” https://www.bmj.com/content/371/bmj.m4257“The T-cell response against the coronavirus nucleoproteins seemed to correlate with the degree of later decline of the antibody response to those proteins, but this did not hold true for the response to the Spike protein (the two were uncorrelated – antibody responses to the Spike protein could go down, while T-cell responses remained).” https://blogs.sciencemag.org/pipeline/archives/2020/11/11/good-news-on-t-cell-response

Phase II kickoff announcement next week.Maybe Lazy Eye Sassine can shake the money tree again and do another dilution?Someone send Dysfunctional Payne an alarm clock to wake up.

Load time

We need so many vaccines for years this one shot is a winner price target in spring 150

LIFETIME OPP on this one guys(HSDT) Market Cap $24 Million / Shares Out 1.4 M / Potential FDA approval for Multiple Sclerosis treatment IMMINENT / UNDISCOVERED stock =LIFETIME OPP potential 20 BAGGER ......GLTAhttps://heliusmedical.com/images/pdf/Fact_Sheet/2020/Fact%20Sheet%20Helius_October%202020%20Approved.pdf

75 later?

News?? Why is this up this much?

Jeff Brown pumped this stock big time in his email today. Let’s see if buyers come in tomorrow

I got in at $67 thinking it was a steal!! I think I'm gonna have to bail. Can't afford to take any more beating.

Approval of highly effective J&J one dose vaccine is eminent

The fact is the public will have to live with COVID for years so different vaccines will always be needed ARCT will be a player for years

Definitely don't expect anything to happen prior the 15th. So many people got duped into buying calls for $100 when this hit $80 for 5mins.

Does anyone know how their Biotech Showcase presentation is going?

80-90 in a few weeks guysHigh target pricesLoad up🚀🚀🚀

Stop whining it’s going over a 100 soon

how many of you got in at $66?